SIFI Merges with Faes Farma to Enhance Ophthalmic Franchise and Global Reach SIFI and Faes Farma's merger will create synergies in ophthalmic markets, expanding access to innovative products globally. The integration aims to optimize operations and accelerate growth.

SIFI Merges with Faes Farma to Enhance Ophthalmic Franchise and Global Reach #Italy #AKANTIOR #SIFI #Catania #Faes_Farma

SIFI's Merger with Faes Farma: A New Era in Ophthalmic Solutions SIFI merges with Faes Farma to enhance its ophthalmic portfolio, expanding access and boosting growth in international markets.

SIFI's Merger with Faes Farma: A New Era in Ophthalmic Solutions #Italy #AKANTIOR #SIFI #Catania #Faes_Farma

SIFI's AKANTIOR® Receives Promising Innovative Medicine Designation in the UK SIFI's AKANTIOR® is now recognized as a Promising Innovative Medicine in the UK, marking a significant milestone for Acanthamoeba keratitis treatment.

SIFI's AKANTIOR® Receives Promising Innovative Medicine Designation in the UK #United_Kingdom #AKANTIOR #SIFI #Acanthamoeba #Catania

SIFI's AKANTIOR® Receives Market Authorization and Innovative Medicine Designation in the UK SIFI announces that AKANTIOR® has received market authorization and the designation of Promising Innovative Medicine in the UK, marking a significant breakthrough for Acanthamoeba keratitis treatment.

SIFI's AKANTIOR® Receives Market Authorization and Innovative Medicine Designation in the UK #United_Kingdom #AKANTIOR #SIFI #Acanthamoeba #Catania

SIFI Granted Marketing Authorization for AKANTIOR® in the UK: A New Hope for Acanthamoeba Keratitis Treatment SIFI announces the marketing authorization and PIM designation for AKANTIOR® in the UK, providing a vital new treatment for Acanthamoeba keratitis.

SIFI Granted Marketing Authorization for AKANTIOR® in the UK: A New Hope for Acanthamoeba Keratitis Treatment #United_Kingdom #AKANTIOR #SIFI #Acanthamoeba #Catania

SIFI's AKANTIOR® Gains Marketing Authorization and Innovative Medicine Designation in the UK SIFI announces that AKANTIOR®, a treatment for Acanthamoeba keratitis, has received marketing authorization and promising innovative medicine designation in the UK.

SIFI's AKANTIOR® Gains Marketing Authorization and Innovative Medicine Designation in the UK #United_Kingdom #AKANTIOR #SIFI #Acanthamoeba #Catania

SIFI Advances Regulatory Pathways for AKANTIOR® Treatment in the UK and US SIFI's regulatory progress for AKANTIOR® in the UK and USA marks a significant milestone in treating acanthamoeba keratitis, showing promise for 2025 approvals.

SIFI Advances Regulatory Pathways for AKANTIOR® Treatment in the UK and US #Italy #AKANTIOR #SIFI #Acanthamoeba #Catania